Comments

;

Comments on 2026 draft letter to issuers in the federally-facilitated exchanges

Nov 4, 2024

In our comments we reiterate our profound disappointment with CCIIO and state regulators for not enforcing the strong ACA nondiscrimination patient protections, including a prohibition on adverse tiering in drug formularies and the requirement to cover the drugs included in widely accepted treatment guidelines. We also outline a number of recent examples by insurers, including some new ones, that either CCIIO or states are permitting to operate that do not protect the interests of people living with HIV since they market discriminatory benefit plans designs.

read more

Support for Oregon enhancing transparency around the use of copay accumulators, copay maximizers, and alternative funding programs

Oct 11, 2024

As the Oregon legislature considers modifications to SB 844, we write to express our support for proposed legislative recommendations including enhancing transparency around the use of copay accumulators, copay maximizers, and alternative funding programs. In recent years, insurers and their PBMs have implemented harmful policies that shift financial responsibilities for prescription costs to patients by not applying copayment assistance from drug manufacturers and sometimes charitable organizations.

read more

Comments to Washington Prescription Drug Affordability Board on HIV treatment and cost of care

Sep 15, 2024

While patients currently have access to free or affordable HIV medications through various avenues, we are concerned that setting an arbitrarily low price for these treatments could negatively impact future drug development and reduce manufacturers’ willingness to continue providing medications to millions of people in underdeveloped and underserved nations. It is essential that manufacturers have the necessary incentives to invest in research and development, enabling the creation of longer-acting treatments, preventive drugs, vaccines, and potentially even a cure for the virus. Overlooking the impact of current assistance programs on HIV treatment affordability, as well as mandating alternative drug options, disregards the nuances of HIV care and the unique requirements of each patient.

read more

Oppose domestic HIV programs cuts of over $541 million in Labor HHS approps. bill

Jul 9, 2024

There are currently over 1.2 million people living with HIV in the United States and approximately 32,000 new diagnoses annually, with only 65 percent of people virally suppressed and only 36 percent of the people who would benefit from PrEP on it. While we are making progress, racial, ethnic, gender, and geographic disparities persist, and continued investments are needed to reduce new infections and bring more people into care and treatment.

read more

Public Comments on Potential Viral Hepatitis Quality Measures in Medicaid

Jun 7, 2024

We support the adoption of quality measures for hepatitis B and hepatitis C in Medicaid. We support the adoption of hepatitis C screening and treatment initiation measures within state Medicaid programs. We urge HHS to consider quality measures for hepatitis B screening and linkage to care, as well as for hepatitis C sustained virological response (SVR) for testing and proposal to the Medicaid Adult Core Set. We support the implementation of hepatitis B screening, hepatitis C screening, and hepatitis C treatment initiation quality measures within state Medicaid programs.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest